The lack of the Celf2a splicing factor converts a Duchenne genotype into a Becker phenotype
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The lack of the Celf2a splicing factor converts a Duchenne genotype into a Becker phenotype
Authors
Keywords
-
Journal
Nature Communications
Volume 7, Issue -, Pages 10488
Publisher
Springer Nature
Online
2016-01-22
DOI
10.1038/ncomms10488
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- How much dystrophin is enough: the physiological consequences of different levels of dystrophin in themdxmouse
- (2015) Caroline Godfrey et al. HUMAN MOLECULAR GENETICS
- The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
- (2015) Catherine L. Bladen et al. HUMAN MUTATION
- Gene Regulatory Networks and Transcriptional Mechanisms that Control Myogenesis
- (2014) Margaret Buckingham et al. DEVELOPMENTAL CELL
- Biogenesis and function of non-coding RNAs in muscle differentiation and in Duchenne muscular dystrophy
- (2013) Shyam Twayana et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy
- (2013) Taeyoung Koo et al. HUMAN GENE THERAPY
- Dystrophin levels and clinical severity in Becker muscular dystrophy patients
- (2013) J. C. van den Bergen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Splicing therapy for neuromuscular disease
- (2013) Andrew G.L. Douglas et al. MOLECULAR AND CELLULAR NEUROSCIENCE
- Genetic Therapeutic Approaches for Duchenne Muscular Dystrophy
- (2012) Helen Foster et al. HUMAN GENE THERAPY
- Exon 45 Skipping Through U1-snRNA Antisense Molecules Recovers the Dys-nNOS Pathway and Muscle Differentiation in Human DMD Myoblasts
- (2012) Valentina Cazzella et al. MOLECULAR THERAPY
- MATS: a Bayesian framework for flexible detection of differential alternative splicing from RNA-Seq data
- (2012) Shihao Shen et al. NUCLEIC ACIDS RESEARCH
- The Effects of Low Levels of Dystrophin on Mouse Muscle Function and Pathology
- (2012) Maaike van Putten et al. PLoS One
- Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials
- (2011) K. Anthony et al. BRAIN
- miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy
- (2011) Davide Cacchiarelli et al. EMBO REPORTS
- Therapeutic approaches to muscular dystrophy
- (2011) A. Goyenvalle et al. HUMAN MOLECULAR GENETICS
- MicroRNAs Involved in Molecular Circuitries Relevant for the Duchenne Muscular Dystrophy Pathogenesis Are Controlled by the Dystrophin/nNOS Pathway
- (2010) Davide Cacchiarelli et al. Cell Metabolism
- Gene therapy for muscle disease
- (2010) Yuko Miyagoe-Suzuki et al. EXPERIMENTAL CELL RESEARCH
- Exon Skipping and Duchenne Muscular Dystrophy Therapy: Selection of the Most Active U1 snRNA Antisense Able to Induce Dystrophin Exon 51 Skipping
- (2010) Tania Incitti et al. MOLECULAR THERAPY
- Tannic acid facilitates expression of the polypyrimidine tract binding protein and alleviates deleterious inclusion of CHRNA1 exon P3A due to an hnRNP H-disrupting mutation in congenital myasthenic syndrome
- (2009) Yang Bian et al. HUMAN MOLECULAR GENETICS
- Long-Term Benefit of Adeno-Associated Virus/Antisense-Mediated Exon Skipping in Dystrophic Mice
- (2008) Michela Alessandra Denti et al. HUMAN GENE THERAPY
- HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment
- (2008) C. Colussi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started